MedPath
HSA Approval

APRITANT IV powder for solution for injection 150mg/vial

SIN16996P

APRITANT IV powder for solution for injection 150mg/vial

APRITANT IV powder for solution for injection 150mg/vial

May 6, 2024

GOLDPLUS UNIVERSAL PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantGOLDPLUS UNIVERSAL PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

INTRAVENOUS

Medical Information

A04AD12

Manufacturer Information

GOLDPLUS UNIVERSAL PTE LTD

MSN Laboratories Private Limited

Active Ingredients

Fosaprepitant Dimeglumine eqv Fosaprepitant

150mg/vial

Fosaprepitant

Documents

Package Inserts

APRITANT IV powder for solution for injection 150 mg per vial PI.pdf

Approved: May 6, 2024

Download

Patient Information Leaflets

APRITANT IV powder for solution for injection 150 mg per vial PIL.pdf

Approved: May 6, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

APRITANT IV powder for solution for injection 150mg/vial - HSA Approval | MedPath